Results 1 to 10 of about 28,903 (211)

Pituitary Apoplexy Following Gonadotropin‐Releasing Hormone Agonist Administration for Prostate Cancer [PDF]

IJU Case Reports
Introduction Pituitary apoplexy represents an uncommon endocrine emergency with potentially life‐threatening consequences. Gonadotropin‐releasing hormone agonist used for prostate cancer has the potential to induce pituitary apoplexy, particularly in the
Masaaki Fujimura, Takahiro Shimizu, Shinichi Sakamoto, Hiroaki Sato, Hiroyoshi Suzuki, Kazuo Mikami   +5 more
doaj   +2 more sources

Gonadotropin-releasing hormone agonist contributes to the successful implementation of in vitro fertilization in a patient with cervical endometriosis: a case report [PDF]

AJOG Global Reports, 2023
This is a case report of a nulliparous young woman who suffered from prolonged menstruation and infertility for 1 year. Magnetic resonance imaging and a transvaginal ultrasound examination revealed cervical endometriosis.
Turui Yang, MD, Jieling Feng, MD, Lu Luo, PhD, Dan Zhang, PhD, Minghui Chen, PhD   +4 more
doaj   +2 more sources

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy [PDF]

Endocrinology, Diabetes & Metabolism Case Reports, 2016
Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Drug-induced pituitary apoplexy is a rare but important consideration when evaluating patients with this presentation.
Fergus Keane, Aoife M Egan, Patrick Navin, Francesca Brett, Michael C Dennedy   +4 more
doaj   +3 more sources

Comparison between the modified long gonadotropin-releasing hormone agonist protocol and the non-downregulation protocol in POSEIDON groups: a propensity score matching retrospective cohort study [PDF]

Frontiers in Endocrinology, 2023
BackgroundIn vitro fertilization (IVF) is the main technique to address the infertility issue in the patient-oriented strategy encompassing individualized oocyte number (POSEIDON) population.
Chunyan Chen, Xinliu Zeng, Hanke Zhang, Qiongqiong Wei, Ying Gao, Lin Liu   +5 more
doaj   +2 more sources

Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2021
Purpose There are few reports on the therapeutic effects of gonadotropin-releasing hormone agonists in boys with central precocious puberty, and studies reported in Korea are very rare.
Ah Young Cho, Su Yeong Ko, Jae Hee Lee, Eun Young Kim   +3 more
doaj   +1 more source

Invitro fertilization outcome in triggering with GnRH agonist, Hcg or combination of GnRH agonist and Hcg [PDF]

Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2020
Introduction: Human chorionic gonadotropin for the final maturation of eggs in the In-vitro fertilization cycle was associated with the possibility of a negative effect on endometrial acceptance, fetal quality and ovarian hyper stimulation syndrome ...
Alamtaj Samsami, Sara Davoodi, Shaghayegh Moradi Alamdarloo, Tahere Poordast, Zahra Shiravani, Azade Morshedzadeh   +5 more
doaj   +1 more source

Obstetric and neonatal outcomes after programmed frozen embryo transfer with or without GnRH agonist for polycystic ovary syndrome: secondary analysis results from a randomized controlled trialAJOG Global Reports at a Glance

AJOG Global Reports, 2023
BACKGROUND: Recent studies have reported higher risks of adverse maternal and neonatal outcomes, such as hypertensive disorders of pregnancy, after programmed frozen embryo transfer, especially in cycles with gonadotropin-releasing hormone agonist ...
Hui-ying Jie, MD, Ruifang Hu, BS, Limei Zhang, MD, Kexin Dong, MD, Chunyan Wu, MD, Qiong Wang, MD, Lu Luo, MD   +6 more
doaj   +1 more source

Luteal-phase support in assisted reproductive technology: An ongoing challenge

International Journal of Reproductive BioMedicine, 2021
It has been shown that in controlled ovarian hyper stimulation cycles, defective luteal phase is common. There are many protocols for improving pregnancy outcomes in women undergoing fresh and frozen in vitro fertilization cycles.
Saeideh Dashti, Maryam Eftekhar
doaj   +1 more source

Luteal Support and Risk of Ovarian Hyperstimulation in Assisted Reproduction (A Review)

Кубанский научный медицинский вестник, 2020
Background. Gonadotropin-releasing hormone agonist as an ovulation trigger effectively reduces the ovarian hyperstimulation risk in in vitro fertilisation protocols, at the same time requiring an effective luteal phase support in embryo transfer cycles ...
V. A. Krutova, A. A. Baklakova
doaj   +1 more source

Cancer Therapy–Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background The risk of cardiac dysfunction for patients with prostate cancer undergoing androgen deprivation therapy (ADT) in the real‐world setting remains unclear.
Dong‐Yi Chen, Cheng‐Hung Lee, Ming‐Lung Tsai, Ming‐Jer Hsieh, Cheng‐Keng Chuang, See‐Tong Pang, Shao‐Wei Chen, Chi‐Nan Tseng, Shang‐Hung Chang, Pao‐Hsien Chu, I‐Chang Hsieh, Victor Chien‐Chia Wu, Wen‐Kuan Huang   +12 more
doaj   +1 more source